Antidepressant Treatment of AIDS Related Depression.
Information source: National Institute of Mental Health (NIMH)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Depression
Intervention: Imipramine hydrochloride (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: GEIGY Pharmaceuticals Official(s) and/or principal investigator(s):
Frances A, Study Chair
Manning D, Study Chair
Summary
To test the effectiveness treating AIDS related depression with imipramine hydrochloride.
Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due
to the relentless course of HIV infection, there is a certain reluctance to treat the
associated depression. In other illness, it has been proven that treating the depression
often results in improvement of overall health status.
This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride
every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating
Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over
phase in which placebo non responders are entered into an open-label study and given
imipramine hydrochloride.
Clinical Details
Study design: Treatment, Placebo Control
Detailed description:
To test the effectiveness treating AIDS related depression with imipramine hydrochloride.
Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due
to the relentless course of HIV infection, there is a certain reluctance to treat the
associated depression. In other illness, it has been proven that treating the depression
often results in improvement of overall health status.
This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride
every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating
Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over
phase in which placebo non responders are entered into an open-label study and given
imipramine hydrochloride.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patient must be ambulatory and relatively good health. Even if unable to work at least
able to partially care care for self and not demented.
- May have been alcoholic or drug abuser 6 months previous.
- Unspecified
- CD4 Unspecified.
Exclusion Criteria:
- Non ambulatory patients or those requiring extensive help in self care are excluded.
- Non ambulatory patients or those requiring extensive help in self care are excluded.
- Current alcohol or drug abuse.
- Unspecified
Locations and Contacts
New York Hosp - Cornell Med Ctr, New York, New York 10021, United States
Additional Information
Last updated: June 23, 2005
|
